{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:18:03Z","timestamp":1787008683400,"version":"build-2736575974"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Extra-intestinal manifestations are frequently reported in inflammatory bowel diseases. However, data comparing the effect of vedolizumab and ustekinumab on articular extra-intestinal manifestations are limited. The aim here was to evaluate differences in new-onset and the evolution of pre-existing joint extra-intestinal manifestations during both treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An international multicentre retrospective study was performed on inflammatory bowel disease patients who started vedolizumab or ustekinumab between May 2010 and December 2020. Extra-intestinal manifestations were assessed at baseline and joint extra-intestinal manifestations were evaluated throughout the 2-year follow-up. Arthropathy was defined by joint inflammation [arthritis\/sacroiliitis], diagnosed by a rheumatologist, and arthralgia as articular pain without confirmed inflammation. Additionally, skin, ocular and hepatic extra-intestinal manifestations were assessed at baseline. Uni- and multivariate analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 911 patients [vedolizumab: 584; ustekinumab: 327] were included. Deterioration of pre-existing arthropathy and rate of new-onset arthropathy were not significantly associated with vedolizumab over ustekinumab. Arthropathy was used as reason to stop treatment in six vedolizumab and two ustekinumab patients. The odds of developing new arthralgia within 6 months was higher in patients who took vedolizumab compared to ustekinumab (adjusted odds ratio [aOR]: 2.28 [1.01\u20135.15], p = 0.047). However, this effect was not sustained during the 2-year follow-up (aOR: 1.35 [0.80-2.29], p = 0.259). Deterioration of pre-existing arthralgia was comparable between ustekinumab and vedolizumab-treated patients. In two vedolizumab-treated patients arthralgia was given as the reason to stop treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Vedolizumab and ustekinumab can be used safely in patients with articular extra-intestinal manifestations. Only a temporary increased risk for developing arthralgia has been observed under vedolizumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjac058","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T15:22:25Z","timestamp":1650381745000},"page":"1676-1686","source":"Crossref","is-referenced-by-count":24,"title":["The Impact of Vedolizumab and Ustekinumab on Articular Extra-Intestinal Manifestations in Inflammatory Bowel Disease Patients: A Real-Life Multicentre Cohort Study"],"prefix":"10.1093","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3704-028X","authenticated-orcid":false,"given":"Cara","family":"De Galan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Paediatrics, Ghent University , Ghent , Belgium"},{"name":"VIB Center for Inflammation Research (IRC), Ghent University , Ghent , Belgium"},{"name":"Ghent Gut Inflammation Group (GGIG), Ghent University , Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Truyens","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Paediatrics, Ghent University , Ghent , Belgium"},{"name":"VIB Center for Inflammation Research (IRC), Ghent University , Ghent , Belgium"},{"name":"Ghent Gut Inflammation Group (GGIG), Ghent University , Ghent , Belgium"},{"name":"Department of Gastroenterology, University Hospital Ghent , Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Peeters","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology , AZ Sint Lucas, Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Mesonero Gismero","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hospital Ramon y Cajal , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainara","family":"Elorza","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hospital de Galdakao , Bilbao , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Torres","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hospital Universitari Germans Trias i Pujol , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liv","family":"Vandermeulen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel , Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aranzazu","family":"Jauregui Amezaga","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital Antwerp , Antwerp , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0469-4332","authenticated-orcid":false,"given":"Rocio","family":"Ferreiro-Iglesias","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hospital Cl\u00ednico Universitario de Santiago, Instituto de Investigaci\u00f3n Sanitaria de Santiago de Compostela (IDIS) , Santiago de Compostela , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Holvoet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital Ghent , Ghent , Belgium"},{"name":"Department of Gastroenterology, AZ Nikolaas , Sint-Niklaas , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4023-8868","authenticated-orcid":false,"given":"Yamile","family":"Zabana","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hospital Universitari M\u00fatua de Terrassa , Barcelona , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas, CIBERehd , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia Peries","family":"Reverter","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hospital Universitari de Girona Doctor Joseph Trueta , Girona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard Bryan","family":"Gonzales","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Paediatrics, Ghent University , Ghent , Belgium"},{"name":"VIB Center for Inflammation Research (IRC), Ghent University , Ghent , Belgium"},{"name":"Nutrition, Metabolism and Genomics Group, Division of Human Nutrition and Health, Wageningen University and Research , Wageningen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Geldof","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Paediatrics, Ghent University , Ghent , Belgium"},{"name":"Department of Gastroenterology, University Hospital Ghent , Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7606-9256","authenticated-orcid":false,"given":"Ga\u00eblle","family":"Varkas","sequence":"additional","affiliation":[{"name":"VIB Center for Inflammation Research (IRC), Ghent University , Ghent , Belgium"},{"name":"Department of Rheumatology, University Hospital Ghent , Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"De Vos","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Paediatrics, Ghent University , Ghent , Belgium"},{"name":"Ghent Gut Inflammation Group (GGIG), Ghent University , Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Triana","family":"Lobat\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Paediatrics, Ghent University , Ghent , Belgium"},{"name":"Department of Gastroenterology, University Hospital Ghent , Ghent , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"2023061313374487700_CIT0001","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","article-title":"Extraintestinal manifestations of inflammatory bowel disease.","volume":"21","author":"Vavricka","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2023061313374487700_CIT0002","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ajg.2009.579","article-title":"The natural history of adult Crohn\u2019s disease in population-based cohorts.","volume":"105","author":"Peyrin-Biroulet","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2023061313374487700_CIT0003","doi-asserted-by":"crossref","first-page":"17463","DOI":"10.3748\/wjg.v20.i46.17463","article-title":"Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients.","volume":"20","author":"Zippi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2023061313374487700_CIT0004","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/ibd\/izy065","article-title":"Extraintestinal manifestations in vedolizumab and anti-tnf-treated patients with inflammatory bowel disease.","volume":"24","author":"Dubinsky","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2023061313374487700_CIT0005","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease.","volume":"10","author":"Harbord","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2023061313374487700_CIT0006","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/gutjnl-2020-322129","article-title":"Emerging treatment options for extraintestinal manifestations in IBD.","volume":"70","author":"Greuter","year":"2021","journal-title":"Gut"},{"key":"2023061313374487700_CIT0007","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/17474124.2019.1574569","article-title":"Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis.","volume":"13","author":"Greuter","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2023061313374487700_CIT0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11894-019-0698-1","article-title":"Extraintestinal manifestations of inflammatory bowel disease: Epidemiology, etiopathogenesis, and management.","volume":"21","author":"Garber","year":"2019","journal-title":"Current Gastroenterol Reports"},{"key":"2023061313374487700_CIT0009","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: A randomised, double blind, placebo controlled trial.","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"2023061313374487700_CIT0010","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s00296-004-0467-8","article-title":"The effect of infliximab on extraintestinal manifestations of Crohn\u2019s disease.","volume":"25","author":"Kaufman","year":"2005","journal-title":"Rheumatol Int"},{"key":"2023061313374487700_CIT0011","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/03009740510026698","article-title":"Infliximab in the treatment of extra-intestinal manifestations of Crohn\u2019s disease.","volume":"5","author":"Rispo","year":"2005","journal-title":"Scan J Rheumatol"},{"key":"2023061313374487700_CIT0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1572-0241.2002.06064.x","article-title":"Improvement of arthritis and arthralgia after treatment with infliximab (remicade) in a German prospective, open-label, multicenter trial in refractory Crohn\u2019s disease.","volume":"97","author":"Herfarth","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"2023061313374487700_CIT0013","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/ard.2008.101659","article-title":"Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: The RAPID 2 study. A randomised controlled trial.","volume":"68","author":"Smolen","year":"2009","journal-title":"Ann Rheym Dis"},{"key":"2023061313374487700_CIT0014","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/ecco-jcc\/jjx117","article-title":"The expanding therapeutic armamentarium for inflammatory bowel disease: How to choose the right drug[s] for our patients?","volume":"12","author":"Hindryckx","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2023061313374487700_CIT0015","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/apt.12639","article-title":"Review article: Anti-adhesion therapies for inflammatory bowel disease.","volume":"39","author":"Lobaton","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"2023061313374487700_CIT0016","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/ecco-jcc\/jjy125","article-title":"Incidence of arthritis\/arthralgia in inflammatory bowel disease with long-term vedolizumab treatment: Post hoc analyses of the GEMINI trials.","volume":"13","author":"Feagan","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2023061313374487700_CIT0017","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ajg.2016.236","article-title":"The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn\u2019s disease: Results from the US victory consortium.","volume":"111","author":"Dulai","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2023061313374487700_CIT0018","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/annrheumdis-2016-210233","article-title":"An induction or flare of arthritis and\/or sacroiliitis by vedolizumab in inflammatory bowel disease: A case series.","volume":"76","author":"Varkas","year":"2017","journal-title":"Ann Rheumat Dis"},{"key":"2023061313374487700_CIT0019","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/apt.13594","article-title":"Vedolizumab induction therapy for inflammatory bowel disease in clinical practice\u2013a nationwide consecutive German cohort study.","volume":"43","author":"Baumgart","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2023061313374487700_CIT0020","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/2050640620965106","article-title":"Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.","volume":"9","author":"Mader","year":"2021","journal-title":"United Eur Gastroenterol J"},{"key":"2023061313374487700_CIT0021","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1093\/ibd\/izy127","article-title":"The association between arthralgia and vedolizumab using natural language processing.","volume":"24","author":"Cai","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2023061313374487700_CIT0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/annrheumdis-2016-211011","article-title":"Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease.","volume":"76","author":"Orlando","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023061313374487700_CIT0023","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.dld.2018.02.017","article-title":"Ustekinumab in the management of Crohn\u2019s disease: Expert opinion.","volume":"50","author":"Armuzzi","year":"2018","journal-title":"Dig Liver Dis"},{"key":"2023061313374487700_CIT0024","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/1744666X.2018.1513329","article-title":"Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases.","volume":"14","author":"Felice","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"2023061313374487700_CIT0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000479475","article-title":"Paradoxical reactions: Anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others.","volume":"53","author":"Puig","year":"2018","journal-title":"Curr Probl Dermatol"},{"key":"2023061313374487700_CIT0026","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis.","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2023061313374487700_CIT0027","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/1744666X.2018.1513329","article-title":"Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases.","volume":"14","author":"Felice","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"2023061313374487700_CIT0028","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ecco-jcc\/jjz119","article-title":"Ustekinumab for Crohn\u2019s disease: Results of the ICC registry, a nationwide prospective observational cohort study.","volume":"14","author":"Biemans","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2023061313374487700_CIT0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rmdopen-2018-000802","article-title":"Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis.","volume":"5","author":"de Winter","year":"2019","journal-title":"RMD open"},{"key":"2023061313374487700_CIT0030","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40265-020-01460-3","article-title":"Vedolizumab and extraintestinal manifestations in inflammatory bowel disease.","volume":"81","author":"Hanzel","year":"2021","journal-title":"Drugs"},{"key":"2023061313374487700_CIT0031","first-page":"511","article-title":"Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: A population study (the IBSEN study).","volume":"29","author":"Palm","year":"2002","journal-title":"J Rheumatol"},{"key":"2023061313374487700_CIT0032","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12178-011-9085-8","article-title":"Inflammatory bowel disease associated arthropathy.","volume":"4","author":"Arvikar","year":"2011","journal-title":"Curr Rev Musculoskelet Med"},{"key":"2023061313374487700_CIT0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2021.640813","article-title":"How to optimize treatment with ustekinumab in inflammatory bowel disease: Lessons learned from clinical trials and real-world data.","volume":"8","author":"Gutierrez","year":"2021","journal-title":"Front Med"},{"key":"2023061313374487700_CIT0034","author":"Review EP.","year":"2019"},{"key":"2023061313374487700_CIT0035","first-page":"1","article-title":"ECCO topical review: Refractory IBD.","volume":"1","author":"Raine","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2023061313374487700_CIT0036","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/MIB.0000000000001039","article-title":"Efficacy and safety of vedolizumab for induction of remission in inflammatory bowel disease\u2014the Israeli real-world experience.","volume":"23","author":"Kopylov","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2023061313374487700_CIT0037","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jbspin.2017.01.012","article-title":"Arthritis occurrence or reactivation under vedolizumab treatment for inflammatory bowel disease. A four cases report.","volume":"85","author":"Wendling","year":"2018","journal-title":"Joint Bone Spine"},{"key":"2023061313374487700_CIT0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/387891","article-title":"Management of musculoskeletal manifestations in inflammatory bowel disease.","volume":"5","author":"Sheth","year":"2015","journal-title":"Gastroenterol Res Practice"},{"key":"2023061313374487700_CIT0039","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/rheumatology\/key267","article-title":"Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease.","volume":"58","author":"Dubash","year":"2019","journal-title":"Rheumatology"},{"key":"2023061313374487700_CIT0040","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/ibd\/izaa293","article-title":"The impact of vedolizumab on pre-existing extraintestinal manifestations of inflammatory bowel disease: A multicenter study.","volume":"27","author":"Ramos","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2023061313374487700_CIT0041","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/apt.14419","article-title":"Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: A multicentre cohort study nested in the OBSERV-IBD cohort.","volume":"47","author":"Tadbiri","year":"2018","journal-title":"Aliment Pharmacol Therap"},{"key":"2023061313374487700_CIT0042","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial.","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"key":"2023061313374487700_CIT0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rmdopen-2019-001149","article-title":"Effects of ustekinumab on spondylitis-associated endpoints in TNFI-naive active psoriatic arthritis patients with physician-reported spondylitis: Pooled results from two phase 3, randomised, controlled trials.","volume":"6","author":"Helliwell","year":"2020","journal-title":"RMD open"},{"key":"2023061313374487700_CIT0044","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/ecco-jcc\/jjab028","article-title":"Effect of ustekinumab on extraintestinal diseases in refractory Crohn\u2019s disease.","volume":"1","author":"Tursi","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2023061313374487700_CIT0045","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/ecco-jcc\/jjaa260","article-title":"Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: A systematic literature review.","volume":"15","author":"Guillo","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2023061313374487700_CIT0046","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.14309\/00000434-201710001-02733","article-title":"Ustekinumab for moderate to severe Crohn\u2019s disease and its extraintestinal manifestations.","volume":"112","author":"Singh","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2023061313374487700_CIT0047","author":"Jansens Cilag SAS.","year":"2018"},{"key":"2023061313374487700_CIT0048","first-page":"69","article-title":"Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn\u2019s disease.","volume":"12","author":"Matsumoto","year":"2018","journal-title":"Biologics: Targets & Therapy"},{"key":"2023061313374487700_CIT0049","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1080\/14712598.2020.1830057","article-title":"Effectiveness of ustekinumab on Crohn\u2018s disease associated spondyloarthropathy: Real-world data from the Sicilian network for inflammatory bowel diseases (SN-IBD).","volume":"20","author":"Macaluso","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"2023061313374487700_CIT0050","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis.","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2023061313374487700_CIT0051","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1056\/NEJMra1909094","article-title":"Reframing immune-mediated inflammatory diseases through signature cytokine hubs.","volume":"385","author":"Schett","year":"2021","journal-title":"N Engl J Med"},{"key":"2023061313374487700_CIT0052","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10620-018-4971-1","article-title":"Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease.","volume":"63","author":"Fleisher","year":"2018","journal-title":"Dig Dis Sci"},{"key":"2023061313374487700_CIT0053","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1093\/rheumatology\/keaa107","article-title":"Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab.","volume":"59","author":"Dupre","year":"2020","journal-title":"Rheumatol"},{"key":"2023061313374487700_CIT0054","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.cgh.2018.09.035","article-title":"Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases.","volume":"17","author":"Meserve","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023061313374487700_CIT0055","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/ecco-jcc\/jjz080","article-title":"Long-term clinical effectiveness of ustekinumab in patients with Crohn\u2019s disease who failed biologic therapies: A national cohort study.","volume":"13","author":"Liefferinckx","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2023061313374487700_CIT0056","first-page":"1","article-title":"Long-term clinical effectiveness of ustekinumab in patients with Crohn\u2019s disease: A retrospective cohort study.","volume":"2","author":"Ito","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2023061313374487700_CIT0057","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ueg2.12094","article-title":"The impact of ustekinumab on extraintestinal manifestations of Crohn\u2019s disease: A post hoc analysis of the UNITI studies.","volume":"5","author":"Narula","year":"2021","journal-title":"United Eur Gastroenterol J"},{"key":"2023061313374487700_CIT0058","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort.","volume":"106","author":"Vavricka","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2023061313374487700_CIT0059","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1111\/j.1572-0241.2005.00233.x","article-title":"Impact","volume":"100","author":"Basu","year":"2005","journal-title":"Am J Gastroenterol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjac058\/46351675\/jjac058.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/11\/1676\/50582910\/jjac058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/11\/1676\/50582910\/jjac058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T09:39:24Z","timestamp":1686649164000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/16\/11\/1676\/6571450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":59,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,4,20]]},"published-print":{"date-parts":[[2022,11,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac058","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,4,20]]}}}